1197-22-4 | N-Phenylmethanesulfonamide

1197-22-4    108-24-7    5317-89-5 

[1]BioorganicandMedicinalChemistryLetters,2004,vol.14,#7,p.1751-1755

1197-22-4    4284-50-8 

[1]Synthesis,2004,p.2809-2812

[2]OrganicLetters,2017,vol.19,p.3799-3802

[3]SyntheticCommunications,2019,vol.49,p.1406-1415

[4]ZhurnalObshcheiKhimii,1959,vol.29,p.3799,3801;engl.Ausg.S.3761

1197-22-4    98-88-4    73153-44-3 

[1]OrganicProcessResearchandDevelopment,2009,vol.13,p.255-262

[2]AngewandteChemie-InternationalEdition,2017,vol.56,p.12718-12722    Angew.Chem.,2017,vol.129,p.12892-12896,5

[3]OrganicLetters,2019,vol.21,p.7976-7981

[4]ZhurnalObshcheiKhimii,1959,vol.29,p.2739;engl.Ausg.S.2706

[5]JournalofMolecularCatalysisA:Chemical,2011,vol.351,p.41-45

[6]OrganicLetters,2017,vol.19,p.1434-1437

[7]Synthesis,2020,vol.52,p.1060-1066

1197-22-4    124-63-0    1207-62-1 

[1]Chemistry-AEuropeanJournal,2016,vol.22,p.16998-17005

[2]JournalofMolecularStructure,2019,vol.1175,p.542-550

[3]JournaloftheAmericanChemicalSociety,1932,vol.54,p.2470,2473

[4]JournaloftheAmericanChemicalSociety,1992,vol.114,p.1743-1749

124-63-0    62-53-3    1197-22-4 

[1]JournalofOrganicChemistry,2003,vol.68,p.5300-5309

[2]OrganicLetters,2019,vol.21,p.1098-1102

[3]Chemistry-AEuropeanJournal,2018,vol.24,p.17215-17219

[4]Patent:US2006/211603,2006,A1.Locationinpatent:Page/Pagecolumn39-40;52-53

[5]JournalofOrganicChemistry,1987,vol.52,p.4377-4379

[6]BioorganicandMedicinalChemistryLetters,2004,vol.14,p.4581-4583

[7]AdvancedSynthesisandCatalysis,2007,vol.349,p.1873-1876

[8]TetrahedronLetters,2008,vol.49,p.348-353

[9]ChemicalCommunications,2014,vol.50,p.10485-10487

[10]JournaloftheAmericanChemicalSociety,2015,vol.137,p.3731-3734

[11]AngewandteChemie-InternationalEdition,2017,vol.56,p.6636-6640    Angew.Chem.,2017,vol.129,p.6736-6740,5

[12]SyntheticCommunications,2004,vol.34,p.3807-3819

[13]Patent:WO2017/18803,2017,A1.Locationinpatent:Paragraph493;494;495

[14]Chemistry-AEuropeanJournal,2016,vol.22,p.16998-17005

[15]Patent:WO2008/73956,2008,A2.Locationinpatent:Page/Pagecolumn66

[16]AngewandteChemie-InternationalEdition,2019,vol.58,p.6650-6653    Angew.Chem.,2019,vol.131,p.6722-6725,4

[17]JournaloftheAmericanChemicalSociety,1992,vol.114,p.1743-1749

[18]JournalofMolecularStructure,2019,vol.1175,p.542-550

[19]Tetrahedron,1996,vol.52,p.14865-14876

[20]SyntheticCommunications,2019,vol.49,p.1406-1415

[21]ZhurnalObshcheiKhimii,1952,vol.22,p.1430,1431;engl.Ausg.S.1473,1474

[22]CanadianJournalofChemistry,1965,vol.43,p.3407-3418

[23]JournalofOrganicChemistry,1984,vol.49,p.249-254

[24]Heterocycles,2001,vol.54,p.105-108

[25]BioorganicandMedicinalChemistry,2000,vol.8,p.2167-2173

[26]JournaloftheAmericanChemicalSociety,2000,vol.122,p.3375-3385

[27]JournalofMolecularCatalysisA:Chemical,2011,vol.351,p.41-45

[28]Synthesis,2012,vol.44,p.1329-1338

[29]Tetrahedron,2012,vol.68,p.3776-3785

[30]ChemicalCommunications,2013,vol.49,p.514-516

[31]EuropeanJournalofOrganicChemistry,2013,p.2775-2779

[32]JournalofOrganicChemistry,2014,vol.79,p.10899-10907

[33]AdvancedSynthesisandCatalysis,2014,vol.356,p.3325-3330

[34]BioorganicandMedicinalChemistryLetters,2016,vol.26,p.757-760

[35]JournalofOrganicChemistry,2016,vol.81,p.7036-7041

[36]OrganicLetters,2017,vol.19,p.1434-1437

[37]BioorganicandMedicinalChemistryLetters,2017,vol.27,p.1989-1992

[38]OrganicLetters,2017,vol.19,p.2006-2009

[39]OrganicLetters,2017,vol.19,p.3823-3826

[40]ACSCatalysis,2016,vol.6

[41]ChemicalCommunications,2019,vol.55,p.4355-4358

1197-22-4    59084-16-1    113558-94-4 

[1]Oinuma,Hitoshi;Miyake,Kazutoshi;Yamanaka,Motosuke;Nomoto,Ken-Ichi;Katoh,Hiroshi;etal.[JournalofMedicinalChemistry,1990,vol.33,#3,p.903-905]

Title: Iguratimod: a new disease-modifying antirheumatic drug.

Journal: Drugs of today (Barcelona, Spain : 1998) 20120901

Title: Highly potent macrocyclic BACE-1 inhibitors incorporating a hydroxyethylamine core: design, synthesis and X-ray crystal structures of enzyme inhibitor complexes.

Journal: Bioorganic & medicinal chemistry 20120715

Title: Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review.

Journal: TheScientificWorldJournal 20120101

Title: Pharmacological management of atrial fibrillation: one, none, one hundred thousand.

Journal: Cardiology research and practice 20110101

Title: In silico analysis of conformational changes induced by mutation of aromatic binding residues: consequences for drug binding in the hERG K+ channel.

Journal: PloS one 20110101

Title: Stereoselective Inhibition of the hERG1 Potassium Channel.

Journal: Frontiers in pharmacology 20100101

Title: Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.

Journal: Biochemical pharmacology 20090515

Title: Non-vanillyl resiniferatoxin analogues as potent and metabolically stable transient receptor potential vanilloid 1 agonists.

Journal: Bioorganic & medicinal chemistry 20090115

Title: Discovery of a novel activator of KCNQ1-KCNE1 K channel complexes.

Journal: PloS one 20090101

Title: N-(4-Chloro-2-nitro-phen-yl)methane-sulfonamide.

Journal: Acta crystallographica. Section E, Structure reports online 20081001

Title: Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.

Journal: Cardiology journal 20080101

Title: Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin.

Journal: Biochemical pharmacology 20070801

Title: Synthesis and biological evaluation of benzopyran analogues bearing class III antiarrhythmic pharmacophores.

Journal: Bioorganic & medicinal chemistry 20061001

Title: Expression and functional phenotype of mouse ERG K+ channels in the inner ear: potential role in K+ regulation in the inner ear.

Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience 20050921

Title: Structural determinants of HERG channel block by clofilium and ibutilide.

Journal: Molecular pharmacology 20040801

Title: A rapidly activating delayed rectifier K+ current regulates pacemaker activity in adult mouse sinoatrial node cells.

Journal: American journal of physiology. Heart and circulatory physiology 20040501

Title: Acceleration of human myoblast fusion by depolarization: graded Ca2+ signals involved.

Journal: Development (Cambridge, England) 20030801

Title: Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency.

Journal: Cardiovascular research 20030301

Title: Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.

Journal: Molecular pharmacology 20011201

Title: Effects of the class III antiarrhythmic agent dofetilide (UK-68,798) on L-type calcium current from rabbit ventricular myocytes.

Journal: The Journal of pharmacy and pharmacology 20011201

Title: An amino acid residue whose change by mutation affects drug binding to the HERG channel.

Journal: FEBS letters 20011012